Intuitive Surgical is rolling out the da Vinci 5 into an installed base of 11,300+ hospitals, growing revenue 23% and EPS 38% year-over-year. Yet shares are down ~31% from 52-week highs because the market is testing one crucial question: does Medtronic or J&J crack the monopoly, or does the dV5 "Platform Refresh" lock down the ecosystem for another decade?
Gray line = ISRG's actual price trajectory ($603 peak Q4 '25 → $396 52-week low → $414 now); colored paths = synthesized scenario midpoints forward, probability-weighted (base 50% · bull 25% · bear 25%). Linear price scale. Wall Street 12-month consensus ≈ $565 (range $366–$650, strong "Buy" skew).
Those probabilities are a judgment call — so make them yours. Drag to set how likely the bear and bull cases are (base takes the remainder); the blended target below, the dotted line on the chart, and the prob-weighted row of the scenario cards all update live.
The same fundamentals support vastly different conclusions depending on which framework you trust. Each lens below is a synthesized expert perspective with its own 12-month target.
Revenue up 23%, EPS up 38%, and Ion procedures exploding +39%. The dV5 rollout with Force Feedback isn't just an upgrade; it's a super-cycle that accelerates hospital replacements. Trading down 30% from its high, the market is mispricing one of the highest-quality, 20%+ compounding assets in MedTech. The premium multiple is a feature, not a bug.
The "Platform Refresh Wall" is here. By aggressively rolling out dV5 into U.S. hospitals now, ISRG secures capital budgets before Medtronic's Hugo or J&J's Ottava can establish a significant US foothold. Add the digital suite (Case Insights, AI training) and extended-use instruments, and switching costs become economically prohibitive.
Look past the P/E ratio and look at the cash engine: 86% recurring revenue (instruments + services), $2.25B in TTM FCF, 39% operating margins, and a balance sheet with absolutely zero long-term debt and nearly $8B in cash. Management retired $1.1B in stock last quarter alone. It's a pristine compounder with a fortress balance sheet.
A multiple near 40-50x requires absolute perfection. However, the dV5 ramp involves initial manufacturing cost headwinds causing gross margin compression. Meanwhile, GLP-1 adoption is structurally impairing bariatric procedure growth. Once Hugo and Ottava clear the FDA, ISRG will finally face a price war, fracturing the monopoly.
What the sell-side expects over the next year. Bars are sorted low to high; the dashed line is today's $414.31 — highlighting the recent dislocation from consensus.
Sell-side 12-month targets — a selection of major firms; the full consensus is ≈ $565, about +36% above today, with a Strong-Buy skew (roughly 65% Strong Buy). The dashed line marks today's $414.31: the recent pullback has left the stock trading below the vast majority of Street expectations, amplifying the debate over whether the selloff is an opportunity or a leading indicator. Firms, ratings, and targets are drawn from recent mid-2026 notes.
Synthesized scenario midpoints (mid-year). Returns shown vs. today's $414.31. These frameworks illustrate how tightly the stock is coiled to its earnings multiple over a 5-year horizon.
The ultimate fundamental safety net. ISRG operates a cash machine with an incredibly strong balance sheet and no long-term debt.
The asset-light nature of ISRG's recurring revenue model: 86% of revenue is tied to instruments and services that carry incredibly high margins. Revenue scales smoothly, and Free Cash Flow follows aggressively, easily covering the modest capex required. The most crucial detail is the black "flatline" — the company carries virtually zero long-term debt, meaning all cash generated is strictly available for R&D fortification and aggressive stock buybacks ($1.1B in Q1 alone). Figures illustrative; trailing FCF.
The base-case valuation model rests on this earnings ladder, plotting non-GAAP EPS growth as the dV5 hardware cycle fuels massive high-margin accessory usage.
Adjusted (non-GAAP) EPS. Gray = reported history, olive = estimates assuming sustained double-digit procedure growth and stable margins despite new tariff pressures. A base case targeting ~$16 of EPS by 2031, married to a compression to ~45x or less exit multiple, yields the mid-$700s targets.
Q1 FY26, year-over-year — compare these operational growth rates against the stock's recent 31% haircut from highs.
The operational strength is profound. EPS (+38%) is scaling significantly faster than Revenue (+23%), showcasing immense operating leverage. Meanwhile, frontier categories (clay) like the Ion endoluminal lung biopsy system (+39%) and the explosive shift in mix toward the new da Vinci 5 (+58% YoY dV5 placement increase) are establishing new, unpenetrated vectors of growth. The stock drop reflects multiple contraction, not operational decay.
The entire valuation argument compresses into one fundamental disagreement: is the moat permanent, or will competitors inevitably fracture it?
Where each risk sits, not just how big it is. The hot upper-right corner — likely and high-impact — is the one that matters; note that the most potent threats to the stock are valuation-driven rather than existential to the business.
At ~40-50x P/E, any minor deceleration in procedure growth forces an immediate re-rating, crushing the share price even if earnings are fine.
Medtronic's Hugo and J&J's Ottava gain clinical validation and finally fracture ISRG's monopoly, triggering a margin-crushing price war.
The mass adoption of GLP-1 weight-loss drugs permanently structurally reduces the need for bariatric surgeries, a key da Vinci procedure.
The dV5 rollout necessitates high initial manufacturing costs, compressing gross margins temporarily and spooking Wall Street algorithms.
A fatal, systemic software or hardware flaw in the new dV5 platform triggers a massive FDA recall, breaking hospital trust.
Volume-Based Procurement (VBP) policies in China, combined with local domestic robotics competitors (e.g. MicroPort), compress OUS margins.
Sustained high interest rates squeeze hospital financing, causing them to delay upgrading to dV5 systems.
Hover the dotted terms in the metrics, or scan the desk's working definitions here.